Precipio Reports Preliminary Financials for FY 2025
- Significant Revenue Growth: Precipio's revenue surged from $18.5 million in 2024 to $24.0 million in 2025, marking a 30% year-over-year increase, which underscores the company's strong market demand and expansion capabilities in cancer diagnostics.
- Improved Adjusted EBITDA: The company reported an Adjusted EBITDA of $1.23 million for FY 2025, a substantial recovery from a loss of $1.5 million in 2024, indicating significant progress in profitability and operational efficiency.
- Positive Cash Flow Performance: Precipio achieved a positive operating cash flow of $688,000 for 2025, up from $439,000 in 2024, reflecting effective financial management and resource allocation.
- Increased Shareholder Value: CEO Ilan Danieli noted that 2025 was a stellar year for the company, with shareholder value tripling, demonstrating confidence in long-term investments and strategic growth initiatives.
Trade with 70% Backtested Accuracy
Analyst Views on PRPO
About PRPO
About the author
Precipio Reports Preliminary Financials for FY 2025
- Significant Revenue Growth: Precipio's revenue surged from $18.5 million in 2024 to $24.0 million in 2025, marking a 30% year-over-year increase, which underscores the company's strong market demand and expansion capabilities in cancer diagnostics.
- Improved Adjusted EBITDA: The company reported an Adjusted EBITDA of $1.23 million for FY 2025, a substantial recovery from a loss of $1.5 million in 2024, indicating significant progress in profitability and operational efficiency.
- Positive Cash Flow Performance: Precipio achieved a positive operating cash flow of $688,000 for 2025, up from $439,000 in 2024, reflecting effective financial management and resource allocation.
- Increased Shareholder Value: CEO Ilan Danieli noted that 2025 was a stellar year for the company, with shareholder value tripling, demonstrating confidence in long-term investments and strategic growth initiatives.
AbbVie Launches New Immunology Drugs, Stock Up 31.6% Over Last Year
- New Drug Launch: AbbVie has successfully launched two new immunology drugs, Skyrizi and Rinvoq, which are expected to support revenue growth in the coming years following Humira's loss of exclusivity.
- Market Performance: AbbVie’s stock has risen 31.6% over the past year, significantly outperforming the 19.5% growth of the large-cap pharmaceuticals industry, indicating strong competitive positioning.
- Acquisition Strategy: The company has engaged in a series of acquisitions over the past few years to bolster its early-stage pipeline, aiming for long-term growth despite challenges from Humira's patent expiration.
- Diversified Product Line: AbbVie's oncology and neuroscience drugs are also contributing to revenue growth, further solidifying its position in the pharmaceutical industry.
Precipio Presents Findings from 895-Patient BCR::ABL1 Assay Study at ASH
- Study Findings Presentation: Precipio will present findings from a joint study with Memorial Sloan Kettering at the ASH meeting, involving 895 patient samples, demonstrating superior performance of the BCR::ABL1 assay, which enhances patient care and optimizes laboratory workflows.
- Significant Clinical Impact: The study shows that the BCR::ABL1 assay exhibits high concordance with two leading platforms, not only improving diagnostic accuracy but also potentially reducing cancer misdiagnosis rates, thereby enhancing treatment outcomes for patients.
- Industry Recognition: The poster presentation and results discussion scheduled for December 8 will further elevate Precipio's standing in the cancer diagnostics field, attracting increased attention and investment.
- Innovation-Driven Growth: Precipio's commitment to developing more efficient diagnostic products to address cancer misdiagnosis is reinforced by these study results, which will drive the company's expansion in the global laboratory market and strengthen its competitive edge.
Precipio Reports Limited Unauthorized Data Access, No Operational Impact
- Incident Overview: Precipio recently identified unauthorized access to a specific data folder within its secure cloud environment, but the incident was limited to the file storage server and did not impact the company's operations, diagnostics processes, or customer services.
- Response Measures: The company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists to assist in the investigation, ensuring system security while resetting passwords company-wide and enhancing monitoring, with no evidence of continued unauthorized access currently found.
- Data Security: Initial investigations indicate that the unauthorized third party accessed and downloaded files primarily containing historical operational procedures, temperature logs, and vendor invoices, which pose no risk or damage to the company, and did not include any patient Social Security numbers or financial information.
- Financial Impact: Precipio maintains a comprehensive cybersecurity insurance policy and expects that costs associated with the investigation and response efforts will be covered according to policy terms, with no anticipated material impact on operations, customers, patient care, or shareholders as a result of this incident.
Precipio Schedules Shareholder Update Call for Q3 2025
Corporate Update Call: Precipio, Inc. will host its Q3-2025 corporate update call on November 17, 2025, at 5:00 PM ET, providing updates on its core businesses and allowing for pre-submitted questions from listeners.
Company Overview: Precipio is a healthcare biotechnology company focused on improving cancer diagnostics to reduce misdiagnoses, enhance laboratory workflow, and improve patient outcomes through innovative diagnostic products and services.
Information Access: Investors and the public can access more information about Precipio through its website and social media platforms, where the company shares disclosures, presentations, and other material information.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance, which are subject to risks and uncertainties, and should not be relied upon as guarantees of future results.
Zacks Analyst Blog Features HSBC, American Express, TotalEnergies, Armanino Foods of Distinction, and Precipio
Zacks Analyst Blog Highlights: The Zacks Equity Research team featured stocks including HSBC Holdings, American Express, TotalEnergies, Armanino Foods, and Precipio, providing insights into their performance and market strategies.
HSBC Performance and Challenges: HSBC's shares have outperformed the foreign banking industry, but restructuring efforts and subdued loan demand may temporarily impact revenue growth despite a strong capital position.
American Express Growth Factors: American Express has seen revenue growth driven by new products and travel spending, but rising expenses and loan loss provisions pose risks to its profitability.
Micro-Cap Stocks Insights: Armanino Foods and Precipio have shown significant year-to-date gains, with Armanino focusing on cost control and expansion, while Precipio is experiencing strong revenue growth but faces liquidity challenges.
Precipio Reports Preliminary Financials for FY 2025
- Significant Revenue Growth: Precipio's revenue surged from $18.5 million in 2024 to $24.0 million in 2025, marking a 30% year-over-year increase, which underscores the company's strong market demand and expansion capabilities in cancer diagnostics.
- Improved Adjusted EBITDA: The company reported an Adjusted EBITDA of $1.23 million for FY 2025, a substantial recovery from a loss of $1.5 million in 2024, indicating significant progress in profitability and operational efficiency.
- Positive Cash Flow Performance: Precipio achieved a positive operating cash flow of $688,000 for 2025, up from $439,000 in 2024, reflecting effective financial management and resource allocation.
- Increased Shareholder Value: CEO Ilan Danieli noted that 2025 was a stellar year for the company, with shareholder value tripling, demonstrating confidence in long-term investments and strategic growth initiatives.
AbbVie Launches New Immunology Drugs, Stock Up 31.6% Over Last Year
- New Drug Launch: AbbVie has successfully launched two new immunology drugs, Skyrizi and Rinvoq, which are expected to support revenue growth in the coming years following Humira's loss of exclusivity.
- Market Performance: AbbVie’s stock has risen 31.6% over the past year, significantly outperforming the 19.5% growth of the large-cap pharmaceuticals industry, indicating strong competitive positioning.
- Acquisition Strategy: The company has engaged in a series of acquisitions over the past few years to bolster its early-stage pipeline, aiming for long-term growth despite challenges from Humira's patent expiration.
- Diversified Product Line: AbbVie's oncology and neuroscience drugs are also contributing to revenue growth, further solidifying its position in the pharmaceutical industry.
Precipio Presents Findings from 895-Patient BCR::ABL1 Assay Study at ASH
- Study Findings Presentation: Precipio will present findings from a joint study with Memorial Sloan Kettering at the ASH meeting, involving 895 patient samples, demonstrating superior performance of the BCR::ABL1 assay, which enhances patient care and optimizes laboratory workflows.
- Significant Clinical Impact: The study shows that the BCR::ABL1 assay exhibits high concordance with two leading platforms, not only improving diagnostic accuracy but also potentially reducing cancer misdiagnosis rates, thereby enhancing treatment outcomes for patients.
- Industry Recognition: The poster presentation and results discussion scheduled for December 8 will further elevate Precipio's standing in the cancer diagnostics field, attracting increased attention and investment.
- Innovation-Driven Growth: Precipio's commitment to developing more efficient diagnostic products to address cancer misdiagnosis is reinforced by these study results, which will drive the company's expansion in the global laboratory market and strengthen its competitive edge.
Precipio Reports Limited Unauthorized Data Access, No Operational Impact
- Incident Overview: Precipio recently identified unauthorized access to a specific data folder within its secure cloud environment, but the incident was limited to the file storage server and did not impact the company's operations, diagnostics processes, or customer services.
- Response Measures: The company immediately initiated its incident response procedures and engaged an external cybersecurity law firm and forensic specialists to assist in the investigation, ensuring system security while resetting passwords company-wide and enhancing monitoring, with no evidence of continued unauthorized access currently found.
- Data Security: Initial investigations indicate that the unauthorized third party accessed and downloaded files primarily containing historical operational procedures, temperature logs, and vendor invoices, which pose no risk or damage to the company, and did not include any patient Social Security numbers or financial information.
- Financial Impact: Precipio maintains a comprehensive cybersecurity insurance policy and expects that costs associated with the investigation and response efforts will be covered according to policy terms, with no anticipated material impact on operations, customers, patient care, or shareholders as a result of this incident.
Precipio Schedules Shareholder Update Call for Q3 2025
Corporate Update Call: Precipio, Inc. will host its Q3-2025 corporate update call on November 17, 2025, at 5:00 PM ET, providing updates on its core businesses and allowing for pre-submitted questions from listeners.
Company Overview: Precipio is a healthcare biotechnology company focused on improving cancer diagnostics to reduce misdiagnoses, enhance laboratory workflow, and improve patient outcomes through innovative diagnostic products and services.
Information Access: Investors and the public can access more information about Precipio through its website and social media platforms, where the company shares disclosures, presentations, and other material information.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance, which are subject to risks and uncertainties, and should not be relied upon as guarantees of future results.
Zacks Analyst Blog Features HSBC, American Express, TotalEnergies, Armanino Foods of Distinction, and Precipio
Zacks Analyst Blog Highlights: The Zacks Equity Research team featured stocks including HSBC Holdings, American Express, TotalEnergies, Armanino Foods, and Precipio, providing insights into their performance and market strategies.
HSBC Performance and Challenges: HSBC's shares have outperformed the foreign banking industry, but restructuring efforts and subdued loan demand may temporarily impact revenue growth despite a strong capital position.
American Express Growth Factors: American Express has seen revenue growth driven by new products and travel spending, but rising expenses and loan loss provisions pose risks to its profitability.
Micro-Cap Stocks Insights: Armanino Foods and Precipio have shown significant year-to-date gains, with Armanino focusing on cost control and expansion, while Precipio is experiencing strong revenue growth but faces liquidity challenges.
